» Articles » PMID: 25843513

Recurrent TERT Promoter Mutations Identified in a Large-scale Study of Multiple Tumour Types Are Associated with Increased TERT Expression and Telomerase Activation

Abstract

Background: Several somatic mutation hotspots were recently identified in the telomerase reverse transcriptase (TERT) promoter region in human cancers. Large scale studies of these mutations in multiple tumour types are limited, in particular in Asian populations. This study aimed to: analyse TERT promoter mutations in multiple tumour types in a large Chinese patient cohort, investigate novel tumour types and assess the functional significance of the mutations.

Methods: TERT promoter mutation status was assessed by Sanger sequencing for 13 different tumour types and 799 tumour tissues from Chinese cancer patients. Thymic epithelial tumours, gastrointestinal leiomyoma, and gastric schwannoma were included, for which the TERT promoter has not been previously sequenced. Functional studies included TERT expression by reverse-transcriptase quantitative polymerase chain reaction (RT-qPCR), telomerase activity by the telomeric repeat amplification protocol (TRAP) assay and promoter activity by the luciferase reporter assay.

Results: TERT promoter mutations were highly frequent in glioblastoma (83.9%), urothelial carcinoma (64.5%), oligodendroglioma (70.0%), medulloblastoma (33.3%) and hepatocellular carcinoma (31.4%). C228T and C250T were the most common mutations. In urothelial carcinoma, several novel rare mutations were identified. TERT promoter mutations were absent in gastrointestinal stromal tumour (GIST), thymic epithelial tumours, gastrointestinal leiomyoma, gastric schwannoma, cholangiocarcinoma, gastric and pancreatic cancer. TERT promoter mutations highly correlated with upregulated TERT mRNA expression and telomerase activity in adult gliomas. These mutations differentially enhanced the transcriptional activity of the TERT core promoter.

Conclusions: TERT promoter mutations are frequent in multiple tumour types and have similar distributions in Chinese cancer patients. The functional significance of these mutations reflect the importance to telomere maintenance and hence tumourigenesis, making them potential therapeutic targets.

Citing Articles

Telomeres and telomerase in mesothelioma: Pathophysiology, biomarkers and emerging therapeutic strategies (Review).

Andreikos D, Spandidos D, Georgakopoulou V Int J Oncol. 2025; 66(3).

PMID: 39981889 PMC: 11844339. DOI: 10.3892/ijo.2025.5729.


Chemotherapeutic 6-thio-2'-deoxyguanosine selectively targets and inhibits telomerase by inducing a non-productive telomere-bound telomerase complex.

Sanford S, Badstubner M, Gerber M, Mannherz W, Lampl N, Dannenberg R bioRxiv. 2025; .

PMID: 39975053 PMC: 11838547. DOI: 10.1101/2025.02.05.636339.


TERTmonitor Efficacy and Performance in Detecting Mutations by Droplet Digital PCR.

Bessa-Goncalves M, Bras J, Jesus T, Prazeres H, Soares P, Vinagre J Genes (Basel). 2024; 15(11).

PMID: 39596624 PMC: 11594489. DOI: 10.3390/genes15111424.


Mechanistic basis of atypical TERT promoter mutations.

Elliott K, Singh V, Backerholm A, Ogren L, Lindberg M, Soczek K Nat Commun. 2024; 15(1):9965.

PMID: 39557834 PMC: 11574208. DOI: 10.1038/s41467-024-54158-5.


Molecular profiling reveals novel therapeutic targets and clonal evolution in ovarian clear cell carcinoma.

Chao A, Huang C, Yu W, Lin C, Lin H, Chao A BMC Cancer. 2024; 24(1):1403.

PMID: 39543535 PMC: 11566382. DOI: 10.1186/s12885-024-13125-5.


References
1.
Liu T, Brown T, Juhlin C, Andreasson A, Wang N, Backdahl M . The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. Endocr Relat Cancer. 2014; 21(3):427-34. PMC: 4045219. DOI: 10.1530/ERC-14-0016. View

2.
Hurst C, Platt F, Knowles M . Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol. 2013; 65(2):367-9. DOI: 10.1016/j.eururo.2013.08.057. View

3.
Populo H, Boaventura P, Vinagre J, Batista R, Mendes A, Caldas R . TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. J Invest Dermatol. 2014; 134(8):2251-2257. DOI: 10.1038/jid.2014.163. View

4.
Davis C, Ricketts C, Wang M, Yang L, Cherniack A, Shen H . The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014; 26(3):319-330. PMC: 4160352. DOI: 10.1016/j.ccr.2014.07.014. View

5.
Wang N, Liu T, Sofiadis A, Juhlin C, Zedenius J, Hoog A . TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer. 2014; 120(19):2965-79. DOI: 10.1002/cncr.28800. View